Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).
J Neurooncol
; 143(3): 583, 2019 Jul.
Article
in En
| MEDLINE
| ID: mdl-31165953
ABSTRACT
The last author's first name was truncated in the initial online publication. The original article has been corrected.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
J Neurooncol
Year:
2019
Document type:
Article
Affiliation country:
United States